產(chǎn)品概述
| 產(chǎn)品名稱(Product Name) | Cleaved-Lamin A (D230) Rabbit Polyclonal Antibody |
| 描述(Description) | Rabbit Polyclonal Antibody |
| 宿主(Host) | Rabbit |
| 應用(Application) | WB,IHC-P,IF-P,IF-F,ICC/IF,ELISA |
| 種屬反應性(Reactivity) | Human,Mouse,Rat |
產(chǎn)品性能
| 偶聯(lián)物(Conjugation) | Unconjugated |
| 修飾(Modification) | Unmodified |
| 同種型(Isotype) | IgG |
| 克?。–lonality) | Polyclonal |
| 形式(Form) | Liquid |
| 存放說明(Storage) | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 儲存溶液(Buffer) | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N. |
| 純化方式(Purification) | Affinity purification |
免疫原
| 基因名(Gene Name) | LMNA |
| 別名(Alternative Names) | LMNA; LMN1; Prelamin-A/C |
| 基因ID(Gene ID) | 4000 |
| 蛋白ID(SwissProt ID) | P02545 |
產(chǎn)品應用
| 稀釋比(Dilution Ratio) | WB 1:500-1:2000, IHC-P 1:100-1:300, ELISA 1:10000, IF-P/IF-F/ICC/IF 1:50-200 |
| 蛋白分子量(Molecular Weight) | 28+75kDa |
研究背景
lamin A/C(LMNA) Homo sapiens The nuclear lamina consists of a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, Apr 2012],disease:Defects in LMNA are a cause of Emery-Dreifuss muscular dystrophy type 2 (EDMD2) [MIM:181350]. EDMD2 is an autosomal dominant disorder characterized by slowly progressive muscle wasting and weakness, early contractures of the elbows Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.,disease:Defects in LMNA are a cause of Emery-Dreifuss muscular dystrophy type 3 (EDMD3) [MIM:604929]. EDMD3 is an autosomal recessive disorder characterized by early contractures, muscle wasting and weakness and cardiomyopathy.,disease:Defects in LMNA are a cause of familial partial lipodystrophy type 2 (FPLD2) [MIM:151660]; also known as familial partial lipodystrophy Dunnigan type. FPLD2 is an autosomal dominant disorder characterized by marked loss of subcutaneous adipose tissue from the extremities and trunk but by excess fat deposition in the head and neck. Frequently associated with profound insulin resistance, dyslipidemia, and diabetes.,disease:Defects in LMNA are a cause of generalized lipoatrophy associated with diabetes, hepatic steatosis, hypertrophic cardiomyopathy and leukomelanodermic papules (LDHCP) [MIM:608056]. LDHCP is a disorder characterized by acquired generalized lipoatrophy with metabolic alterations, massive liver steatosis, distinctive cutaneous manifestations, and cardiac abnormalities involving both endocardium and myocardium.,disease:Defects in LMNA are a cause of lethal tight skin contracture syndrome [MIM:275210]; also called restrictive dermopathy (RD). Lethal tight skin contracture syndrome is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance.,disease:Defects in LMNA are a cause of tendinous calcinosis arthropathy and progeroid features (TCAPF) [MIM:611618]. This disorder consists of an autosomal recessive arthropathy syndrome affecting predominantly the distal femora and proximal tibia in the knees with tendinous calcifications, associated with progeroide appearance, such as pinched nose and micrognathia, cataract, alopecia, generalized lipodystrophy and sclerodermatous skin.,disease:Defects in LMNA are a cause of Werner syndrome (WRN) [MIM:277700]. WRN is an autosomal, recessively inherited, segmental progeroid syndrome, in which multiple aspects (or segments) of aging phenotypes seem to be entailed. The features of Werner syndrome are scleroderma-like skin changes, especially in the extremities, cataract, subcutaneous calcification, premature arteriosclerosis, diabetes mellitus, and a wizened and prematurely aged facies.,disease:Defects in LMNA are the cause of cardiomyopathy dilated type 1A (CMD1A) [MIM:115200]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.,disease:Defects in LMNA are the cause of Charcot-Marie-Tooth disease type 2B1 (CMT2B1) [MIM:605588]. CMT2B1 is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2B1 inheritance is autosomal recessive.,disease:Defects in LMNA are the cause of heart-hand syndrome Slovenian type [MIM:610140]. Heart-hand syndrome (HHS) is a clinically and genetically heterogeneous disorder characterized by the co-occurrence of a congenital cardiac disease and limb malformations.,disease:Defects in LMNA are the cause of Hutchinson-Gilford progeria syndrome (HGPS) [MIM:176670]. HGPS is a rare genetic disorder characterized by features reminiscent of marked premature aging.,disease:Defects in LMNA are the cause of limb-girdle muscular dystrophy type 1B (LGMD1B) [MIM:159001]. LGMD1B is an autosomal dominant degenerative myopathy with age-related atrioventricular cardiac conduction disturbances, dilated cardiomyopathy, and the absence of early contractures. LGMD1B is characterized by slowly progressive skeletal muscle weakness of the hip and shoulder girdles. Muscle biopsy shows mild dystrophic changes.,disease:Defects in LMNA are the cause of mandibuloacral dysplasia with type A lipodystrophy (MADA) [MIM:248370]. Mandibuloacral dysplasia (MAD) is a rare autosomal recessive disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, joint contractures, and types A or B patterns of lipodystrophy. Type A lipodystrophy observed in MADA, is characterized by fat loss restricted to the extremities.,function:Lamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals.,miscellaneous:The structural integrity of the lamina is strictly controlled by the cell cycle, as seen by the disintegration and formation of the nuclear envelope in prophase and telophase, respectively.,miscellaneous:There are three types of lamins in human cells: A, B, and C.,PTM:Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.,PTM:The C-terminal 18 residues are removed by proteolytic cleavage in isoform A. Proteolytic cleavage requires prior farnesylation and absence of farnesylation blocks cleavage.,similarity:Belongs to the intermediate filament family.,subunit:Homodimer of lamin A and lamin C. Interacts with lamin-associated polypeptides IA, IB and TMPO-alpha, RB1 and with emerin. Interacts with SREBF1, SREBF2 and TMEM43 (By similarity). Proteolytically processed isoform A interacts with NARF.,
研究領域
Hypertrophic cardiomyopathy (HCM);Arrhythmogenic right ventricular cardiomyopathy (ARVC);Dilated cardiomyopathy;
關鍵字: LMNA;Cleaved-Lamin;A;(D230);Rabbit;Polyclonal;Antibody;一抗
武漢恩璣生命科技有限公司(EnkiLife)是一家深耕生命科學,專注細胞生物學和免疫學科研試劑的研發(fā)、生產(chǎn)與銷售的生物技術企業(yè),在全球100多個國家和地區(qū)開展業(yè)務,致力于為科研工作者提供高質(zhì)量的產(chǎn)品和卓越的客戶服務,推動生命科學的發(fā)展。
EnkiLife的產(chǎn)品線涵蓋細胞系、原代細胞、細胞培養(yǎng)基、血清、細胞檢測試劑盒、重組靶點蛋白、細胞因子、重組抗體、ELISA試劑盒、生化試劑盒等,并提供技術服務與定制開發(fā),覆蓋了生命科學研究的各大關鍵領域,包括細胞生物學、癌癥、免疫學、神經(jīng)科學、心血管疾病、干細胞、表觀遺傳學、內(nèi)分泌、蛋白質(zhì)組學、代謝組學等,全方位滿足您的實驗需求,讓您享受科研的樂趣!
公司現(xiàn)已建立四大技術平臺:
EnCyto?細胞培養(yǎng)及檢測平臺:擁有細胞系庫(500+)、原代細胞庫(500+)、基礎培養(yǎng)基和完全培養(yǎng)基(1200+)
EnkiPro?重組蛋白平臺:現(xiàn)貨產(chǎn)品2000+,可提供定制化表達服務
EnAb?重組抗體平臺:重組兔單抗(3000+),可提供定制化和標記服務
EnKits?試劑盒開發(fā)平臺:可提供優(yōu)質(zhì)的ELISA試劑盒、配套試劑、抗體對、生化試劑盒等相關產(chǎn)品
EnkiLife在生產(chǎn)管理方面引入ISO9001質(zhì)量管理體系和信息化、自動化的管理工具,擁有高效穩(wěn)定的交付能力,與全球知名品牌建立了緊密的合作。
EnkiLife始終堅持以技術創(chuàng)新為驅(qū)動,以匠心鑄就品質(zhì),以品質(zhì)服務客戶。
我們期待與更多的全球科研工作者和企業(yè)攜手合作,共同推動生命科學領域的進步與發(fā)展。